Drug intelligence / Profile preview

sB24M

Development stage: Phase 1
Lead developer: SWISS BIOPHARMA MED
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Topical, Local Injection

Overview

sB24M is a monoclonal antibody developed as a protein-based therapy using biotechnology methods. It acts as an inhibitor and modulator of the CD47 and tumor necrosis factor (TNF, specifically TNF-α) pathways. The drug is designed to negatively regulate immune-inflammatory processes through the CD47/TNF-α axis, thereby promoting epithelialization and healing of damaged tissue. Its primary clinical development has focused on topical or local injection for severe forms of pyoderma gangrenosum, a rare skin disease characterized by chronic ulcerative lesions. The drug was initially developed by SWISS BIOPHARMA MED GmbH[1][2][4].

Other names: Monoclonal antibody (Mab) sB24M

Targets

CD47 (Cluster of Differentiation 47)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on sB24M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sB24M.